Special Edition: What's Next—Cortisol, Metabolism & Future Innovation, Part 4

About this episode

This episode explores the effects of hypercortisolism on difficult-to-treat diabetes and resistant hypertension.

Is hypercortisolism the hidden culprit in a significant proportion of both difficult-to-treat diabetes and resistant hypertension? In part 4 of our special series, Dr. Neil Skolnik speaks with John Buse, MD to explore the effects of hypercortisolism, until just recently considered a vanishingly rare condition. This special episode is sponsored with support from Corcept . Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts , Amazon Music , Spotify , or your preferred podcast platform. Presented by: Neil Skolnik , MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John Buse , MD, The Verne S. Caviness Distinguished Professor and director of the Diabetes Center at the University of North Carolina at Chapel Hill School of Medicine, a past president of medicine & science at the American Diabetes Association (ADA), and recipient of the ADA Outstanding Achievement in Clinical Diabetes Research Award Selected references: Prevalence of Hypercortisolism in…

People in this episode

Host: Neil Skolnik

Guest: John Buse

Topics covered

• hypercortisolism
• diabetes
• resistant hypertension
• metabolism
• future innovation

Keywords

• hypercortisolism
• diabetes
• resistant hypertension
• metabolism
• innovation
• treatment
• clinical research

Sponsors

Corcept

Mentioned in this episode

Organizations: American Diabetes Association

Books & works: Diabetes Care

More episodes of DOC Updates

• Special Edition: Hypertension Part 2—Advanced Hypertension Management: Uncontrolled and Resistant Hypertension and the Importance of Aldosterone · September 8, 2026 · 40 min
• Special Edition: Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH) · September 3, 2026 · 23 min
• Special Edition: Evidence-Based Strategies for Weight Loss and Long-Term Weight Maintenance · August 24, 2026 · 32 min
• Special Edition: What's Next—The Role of Health Systems in Managing CKD Associated with T1D & T2D · August 17, 2026 · 33 min
• Katherine Tuttle on SGLT2s & CKD in T2D, Alexander Turchin on medications after Metformin, and High vs. Low CVD Risk, the ADA's statement on employment and diabetes, and more! · August 10, 2026 · 36 min
• Impact of Finerenone on Albuminuria in T1D, National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs, and more! · August 10, 2026 · 32 min